Unlike sub-Saharan African countries, Brazil will not get discounts on two Acquired Immuno Deficiency Syndrome (aids) drugs that us-based Merck and Co Incorporation is planning to offer. "The discount on crixivan and stocrin is not applicable to Brazil," said Marcos Levy, director of corporate affairs at Merck's Brazil unit. Responding to this, the Brazilian government has announced that it will violate Merck's patent and start producing at least one of those drugs by June 2001, if the prices are not lowered. The country has a law that allows it to manufacture aids drugs, even if it means revoking patents, because of which it has invited the wrath of the pharmaceutical industry.
Brazil suffers from a high rate of aids infection. So far, 190,000 cases have been registered, but the treatment is very expensive for most Brazilians.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.